Institutional Investment Surge: Recent chatter on X about Rein Therapeutics Inc. (RNTX) has centered on significant institutional investments. Posts highlight a major acquisition of over 500,000 shares by a university investment management company in the second quarter. Another firm also reportedly invested around $43,000 in the stock during the same period.
Funding Agreement Buzz: Discussion on X also focuses on a recent $1 million pre-paid advance deal announced by the company. Users are noting this as part of a larger $6 million funding arrangement over the past year. The issuance of nearly 2 million shares to offset advances has sparked curiosity about future growth plans.
Note: This discussion summary was generated from an AI condensation of post data.
Rein Therapeutics Inc. Insider Trading Activity
Rein Therapeutics Inc. insiders have traded $RNTX stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RNTX stock by insiders over the last 6 months:
- CAPITAL, LP VOSS has made 4 purchases buying 306,050 shares for an estimated $423,465 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Rein Therapeutics Inc. Hedge Fund Activity
We have seen 0 institutional investors add shares of Rein Therapeutics Inc. stock to their portfolio, and 1 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- AVION WEALTH removed 200 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $280
- EXENCIAL WEALTH ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Rein Therapeutics Inc. Analyst Ratings
Wall Street analysts have issued reports on $RNTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/22/2025
To track analyst ratings and price targets for Rein Therapeutics Inc., check out Quiver Quantitative's $RNTX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
